Skip to main content
SpringerLink
Log in

Gouty arthritis: Understanding the disease state and management options in primary care

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Acute gouty arthritis is an inflammatory response triggered by the release of monosodium urate crystal deposits into the joint space. The disease is associated with debilitating clinical symptoms and functional impairments as well as adverse economic and quality-of-life burdens. Because gouty arthritis is typically diagnosed and managed in the primary care setting, clinicians require a thorough knowledge of the presenting clinical features, risk factors, differential diagnoses, and treatment options for appropriate management. Although generally effective, the use of currently available therapies to control gouty arthritis is challenging because many medications used to treat comorbidities can exacerbate gouty arthritis and because current agents are associated with a number of adverse events, contraindications, or both. Based on an understanding of the underlying inflammatory pathogenesis of gouty arthritis, several new agents are being developed that may provide improved efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Martinon F. Update on biology: uric acid and the activation of immune and inflammatory cells. Curr Rheumatol Rep. 2010;12:135–141.

    Article  PubMed  CAS  Google Scholar 

  2. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8(suppl. 1):S1.

    Article  PubMed  Google Scholar 

  3. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75(suppl. 5):S5–S8.

    Article  PubMed  Google Scholar 

  4. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76:801–808.

    PubMed  Google Scholar 

  5. Becker MA, Ruoff GE. What do I need to know about gout? J Fam Pract. 2010;59(suppl. 6):S1–S8.

    PubMed  Google Scholar 

  6. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med. 2007;120:221–224.

    Article  PubMed  Google Scholar 

  7. Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: The National Health and Nutrition Examination Survey (NHANES). Arthritis Rheum. 2010;62:S901–S902.

    Google Scholar 

  8. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl. 1):S2.

    Article  PubMed  Google Scholar 

  9. Lee SJ, Hirsch JD, Terkeltaub R, et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009;48:582–586.

    Article  Google Scholar 

  10. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894–900.

    Article  PubMed  Google Scholar 

  11. Mapa JB, Pillinger MH. New treatments for gout. Curr Opin Investig Drugs. 2010;11:499–506.

    PubMed  CAS  Google Scholar 

  12. Martinon F, Petrilli V, Mayor A, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241.

    Article  PubMed  CAS  Google Scholar 

  13. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301–1311.

    Article  PubMed  CAS  Google Scholar 

  14. Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van WC, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170:1120–1126.

    Article  PubMed  Google Scholar 

  15. Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75(suppl. 5):S17–S21.

    Article  PubMed  Google Scholar 

  16. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895–900.

    Article  PubMed  CAS  Google Scholar 

  17. Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29:1950–1953.

    PubMed  CAS  Google Scholar 

  18. Thiele RG. Role of ultrasound and other advanced imaging in the diagnosis and management of gout. Curr Rheumatol Rep. 2011;13:146–153.

    Article  PubMed  Google Scholar 

  19. Tolin MC, Navarra SV. Severe hip and knee pain in a man with chronic tophaceous gout. Int J Rheum Dis. 2009;12:57–60.

    Article  PubMed  Google Scholar 

  20. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol. 2005;17:319–324.

    Article  PubMed  CAS  Google Scholar 

  21. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218–227.

    Article  PubMed  CAS  Google Scholar 

  22. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312–1324.

    Article  PubMed  CAS  Google Scholar 

  23. Celebrex(celecoxib capsules) [product information]. New York, NY: Pfizer Inc.; 2011.

  24. Napralen(naproxen sodium controlled-released tablets) [product information]. San Diego, CA: Victory Pharma, Inc.; 2011.

  25. Colcrys™ (colchicine, USP tablets for oral use) [product information]. Corona, CA: Mutual Pharmaceutical Company, Inc.; 2009.

  26. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060–1068.

    Article  PubMed  CAS  Google Scholar 

  27. Prednisone tablets USP [product information]. Columbus, OH: Roxane Labratories, Inc.; 2002.

  28. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008:CD005521.

  29. Mandell BF, Edwards NL, Sundy JS, Simkin PA, Pile JC. Preventing and treating acute gout attacks across the clinical spectrum: a roundtable discussion. Cleve Clin J Med. 2010;77(suppl. 5). S2–S25.

    Article  PubMed  Google Scholar 

  30. Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Reumatologica Portuguesa. 2010;35:466–474.

    PubMed  CAS  Google Scholar 

  31. ALLOPURINOL (allopurinol tablet) [product information]. Corona, CA: Watson Laboratories, Inc.; 2006.

  32. ULORIC® (Febuxostat tablet for oral use) [product information]. Deerfield, Ill: Takeda Pharmaceuticals America, Inc.; 2009.

  33. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.

    Article  PubMed  Google Scholar 

  34. PROBENECID [product information]. Corona, CA: Watson Pharmaceuticals Inc.; 2011.

  35. KRYSTEXXA™ (pegloticase) Injection, for intravenous infusion [product information]. East Brunswick, NJ: Savient Pharmaceuticals, Inc.; 2010.

  36. Baraf HS, Becker MA, Edwards NL, et al. Tophus response to peloticase (PGL) therapy: pooled results of GOUT 1 and GOUT 2 PGL phase 3 randomized, doubleblind, placebo-controlled trials. Arthritis Rheum. 2008;58(suppl. 9):S176.

    Google Scholar 

  37. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.

    Article  PubMed  Google Scholar 

  38. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra’s efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210–214.

    Article  PubMed  CAS  Google Scholar 

  39. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebocontrolled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–1617.

    Article  PubMed  CAS  Google Scholar 

  40. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064–3076.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas Medical Branch (UTMB), 2060 Space Park Drive, Suite 208, Nassau Bay, TX, 77058, USA

    Prashanth Sunkureddi

Authors
  1. Prashanth Sunkureddi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prashanth Sunkureddi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sunkureddi, P. Gouty arthritis: Understanding the disease state and management options in primary care. Adv Therapy 28, 748–760 (2011). https://doi.org/10.1007/s12325-011-0058-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0058-5

Keywords

Search

Navigation